Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Apogee Therapeutics, Inc.NASDAQ: APGE
Short-term Investments · Q2 FY2026 · quarter ended Jun 2026
Short-term investments rises 127.3% from a year ago
Short-term investments stood at $866.36M at the end of Q2 FY2026, up 127.3% from a year earlier and up 42.5% from the prior quarter.
Context
- Short-term investments amounted to 64.9% of total assets at the end of Q2 FY2026, up 6.9 pp from a year earlier.
- Short-term investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +127.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 598.64M USD
- Year-over-year change
- +58.0%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 598.64M | +58.0% |
| FY2024 | 2024-12-31 | 378.86M | +36.7% |
| FY2023 | 2023-12-31 | 277.14M | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Investments vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +127.3% is the 3rd highest of 8, against a peer median of +24.7%.
- Short-term investments amounts to 64.9% of total assets for APGE, versus a peer median of 33.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $956.21M USD | +50.6% | +134.1% | 91.4% | |
| Sep 2026 | $868.24M USD | +142.7% | -13.2% | 72.4% | |
| Jun 2026 | $866.36M USD | +127.3% | — | 64.9% | |
IRONDisc Medicine, Inc. | Sep 2026 | $592.83M USD | +24.7% | — | 84.8% |
| Jun 2026 | $572M USD | +368.7% | +24.2% | 69.1% | |
| Sep 2026 | $391.8M USD | -45.1% | -42.0% | 23.3% | |
| Mar 2026 | $238M USD | -35.2% | -25.0% | 18.4% | |
| Mar 2026 | $214.16M USD | +19.4% | — | 33.4% | |
| Jun 2026 | $10M USD | — | — | 0.9% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥0 CNY | — | — | 0.0% |
| Peer median (excluding APGE) | — | +24.7% | -13.2% | 33.4% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.